MUMBAI

541 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
541
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
4
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

MUMBAI

  1. 1. MUMBAI 1ST GLOBAL INSIGHT CONFERENCE ON LEUKAEMIA 10-11 September 2007 Mumbai, India Chair: S. Advani, IN - F. Cavalli, CH - J. Goldman, UK Scientific Co-ordinator: T. Mughal, US Host Co-ordinator: S. Koppikar, IN he l e. GLOBAL INSIGHT CONFERENCES In partnership with International Network for Cancer Treatment and Research In collaboration with
  2. 2. FACULTY M. Agarwal, Bombay Hospital Institute of Medical Sciences, Dept. of Haematology, Mumbai, IN S. Agarwal, Sir Gangaram Hospital, Dept. of Medical Oncology, New Delhi, IN S. Advani, Jaslok Hospital and Asian Institute of Oncology, Dept. of Medical Oncology, Mumbai, IN S. Banavali, Tata Memorial Hospital, Dept. of Haematology and Medical Oncology, Mumbai, IN F. Cavalli, Oncology Institute of Southern Switzerland, Div. of Medical Oncology, Bellinzona, CH M. Chandy, Christian Medical College Hospital, Dept. of Haematology, Vellore, IN R. Chopra, Intraprastha Apollo Cancer Institute, Dept. of Medical Oncology, New Delhi, IN J. Goldman, Hammersmith Hospital at Imperial College, Dept. of Leukaemia Biology, London, UK S. Koppikar, Bombay Hospital Institute of Medical Sciences, Dept. of Medical Oncology, Mumbai, IN R. Kumar, All India Institute of Medical Sciences, Dept. of Haematology, New Delhi, IN P. Kurkure, Tata Memorial Hospital, Dept. of Paediatric Oncology, Mumbai, IN F. Jijna, KEM Hospital, Dept. of Haematology, Mumbai, IN X. Hao, Medical University of Tianjin, CN B. Lowenberg, Erasmus University Medical Centre, Dept. of Haematology, Rotterdam, NL I. Magrath, International Network for Cancer Treatment and Research, Brussels, BE H. Malhotra, SMS Medical College, Dept. of Medical Oncology, Jaipur, IN G. Mufti, King’s College Hospital, Dept. of Haematology, London, UK T. Mughal, University of Texas Southwestern School of Medicine, Dept. of Haematology, Dallas, US V. Nair, Ary Hospital Research and Referral Centre, Dept. of Haematology and Bone Marrow Transplantation, New Delhi, IN R. Parikh, Tata Memorial Cancer Centre, Dept. of Medical Oncology, Mumbai, IN S. Parikh, Haematology Lab Clinic, Mumbai, IN P.G. Pelicci, European Institute of Oncology, Div. of Experimental Oncology, Milan, IT R. Powles, Parkside Hospital Oncology Centre, Myeloma and Leukaemia Unit, London, UK V. Raina, All India Institute of Medical Sciences, Dept. of Medical Oncology, New Delhi, IN D. Raghunadhrao, NIMS, Dept. of Medical Oncology, Hyderabad, IN T. Saikia, Prince Ali Khan Hospital, Dept. of Medical Oncology, Mumbai, IN P.M. Shah, Gujrat Cancer Research Institute, Dept. of Medical Oncology, Ahmedabad, IN A.K. Vaid, Rajiv Gandhi Cancer Institute, Dept. of Medical Oncology, New Delhi, IN
  3. 3. BACKGROUND AND SCOPE Current estimates suggest that over 11 million people are diagnosed with cancer globally and sadly over 8 million die from cancer-related causes annually. The European School of Oncology (ESO) has had a significant commitment over the past two decades in contributing towards an improved cancer care, ranging from preventive and screening measures to the education of the cancer care team in general. The ESO Global Insight Conference should add a further dimension by focusing on specific cancers in multiple geographic locations to develop a good infrastructure for improving patients' outcomes through education. The inaugural programme for this series should address adult and childhood leukaemias, an area in which significant advances in many aspects, including molecular understanding, better diagnostic and risk stratifications, classifications and therapies, in particular molecularly targeted therapies. Leukaemias, in particular chronic myeloid leukaemia, promises to revolutionize the treatments of cancers in general and the lessons learned have resulted in the successful application of targeted therapies for many common cancers. Supportive and adjunctive therapies have also improved and the local applicability of such treatments will also be addressed. TARGET AUDIENCE Scientists, adult and paediatric haematologists, oncologists, pathologists and other members of the health discipline involved in the care of patients with leukaemias.
  4. 4. PRELIMINARY PROGRAMME MONDAY, 10 SEPTEMBER 8:00 Welcome and introduction F. Cavalli, CH - T. Mughal, US 8:05 Welcome from UICC A. Kurkure, IN 8:10 An INCTR Award-recipient lecture: An Indian perspective of leukaemias S. Advani, IN 8:40 Session 1: What is the basis of the biological heterogeneity of leukaemias? Moderators: V. Nair, IN - P.G. Pelicci, IT Acute leukaemias P.G. Pelicci, IT Chronic leukaemias J. Goldman, UK Myelodysplastic syndromes G. Mufti, UK Discussion 10:30 Coffee break 11:00 Session 2 Current classification and risk stratification methods Moderators: G. Mufti, UK - D. Raghunadhrao, IN Acute myeloid leukaemia B. Lowenberg, NL Acute lymphoblastic leukaemia (adults) R. Powles, UK Myelodysplastic syndromes G. Mufti, UK Chronic myeloid leukaemia J. Goldman, UK Chronic lymphocytic leukaemia F. Cavalli, CH Discussion 12:30 Lunch break 13:30 Session 3 Integrating novel therapies into current treatment algorithms Moderators: T. Mughal, US - S. Parikh, IN Acute myloid leukaemia B. Lowenberg, NL Acute promyelocytic leukaemia P.G. Pellici, IT Myelodysplastic syndromes G. Mufti, UK 15 16 TU 8: 9: 11 11
  5. 5. Acute lymphocytic leukaemia R. Powles, UK Chronic myeloid leukaemia T. Mughal, US Chronic lymphocytic leukaemia F. Cavalli, CH Discussion 15:30 Coffee break 16:00 Session 4 Case-presentations and discussions Moderators: S. Agarwal, IN - J. Goldman, UK Acute promyelocytic leukaemia M. Chandy, IN Chronic myloid leukaemia - CP M. Agarwal, IN Chronic myloid leukaemia - TKI resistant R. Parikh, IN Myelodysplastic syndromes - high-risk X. Hao, CN Acute myeloid leukaemia T. Saikia, IN Chronic lymphocytic leukaemia - high-risk S. Koppikar, IN TUESDAY, 11 SEPTEMBER 8:30 Keynote lectures Moderators: P. Kurkure, IN - R. Powles, UK Childhood leukaemias I. Magrath, BE Non myeloablative stem cell transplantation J. Goldman, UK 9:30 Session 5 Minimal residual disease Moderators: F. Jijna, IN - B. Lowenberg, NL Concepts B. Lowenberg, NL Methodology (1): Immunophenotyping R. Powles, UK Methodology (2): Molecular J. Goldman, UK 11:00 Coffee break 11:30 Session 6 Supportive care issues Moderators: I. Magrath, BE - A.K. Vaid, IN Growth factors B. Lowenberg, NL 12 14 15 16 17
  6. 6. Innovations in supportive care R. Kumar, IN Elderly leukaemias R. Powles, UK Case-based discussions: - General S. Banavali, IN - Acute myeloid leukaemia in the elderly H. Malhotra, IN 12:45 Lunch break 14:00 Session 7 Pharmaco-economics Moderator: P.M. Shah, IN A US perspective T. Mughal, US A European perspective F. Cavalli, CH An Indian perspective V. Raina, IN A Chinese perspective X. Hao, CN Optimising cost-effective treatment algorithms J. Goldman, UK 15:30 Coffee break 16:00 Session 8 Special issues Moderators: F. Cavalli, CH - R. Chopra, IN Leukaemia research in the emerging world I. Magrath, BE Establishing global clinical trials networks for haematological malignancies All faculty members 17:30 Closing remarks F. Cavalli, CH 1S PA Su Ins De Cit St Zip Te (wi Em Fis (on Pr Sp Ma RE Pa Th co PA Ca Ca Ca Ba Ac Nu IBA Re Ple I a Ava Si
  7. 7. GENERAL INFORMATION MUMBAI QUALITY SYSTEM MANAGEMENT CERTIFIED COURSE VENUE The conference will be held at the Taj President Hotel, 90 Cuffe Parade, Mumbai. ORGANISING SECRETARIAT Chatrina Melcher European School of Oncology - Bellinzona Office Oncology Institute of Southern Switzerland Ospedale Reg. Bellinzona e Valli CH-6500 Bellinzona, Switzerland Tel: +41 91 811 8050 - Fax: +41 91 811 8051 Email: eso2@esoncology.org INFORMATION AND ONLINE REGISTRATION AVAILABLE AT: www.cancerworld.org/eso Registration Registration may be required online (www.cancerworld.org/eso) or by returning the enclosed registration form. The registration fee of € 35 applies to participants resident in India or surrounding countries; the fee for international participants is € 270. Club ESO members will be granted the reduction of 20% on the international fee. Registration includes access to all sessions, coffee breaks and lunches, a copy of the programme book. The registration deadline is 3 September 2007. On-site registration is granted on availability only Confirmation of registration Registration will be confirmed by mail, fax or e-mail. Cancellation of registration In case of cancellation without replacement, the fee less handling charges of € 15 for local participants and € 100 for international participants, will be refunded provided a written request is received by the European School of Oncology before 6 August 2007. No refund can be made if notice of cancellation is received after this date. Refunds will be settled after the conference only. Replacements will be accepted only before 6 August 2007. Accommodation As reference, participants may refer to: Taj President Mumbai Tel: +91 22 6665 0808 - Email: president.mumbai@tajhotels.com The list of other hotels of reference is available at: www.cancerworld.org/eso Certificates All participants will be issued with a certificate of attendance at the close of the conference. Official language The official language of the course will be English. No simultaneous translation will be provided. Badge The badge is the only official evidence of registration and should be worn at all times during the course. Loss of badge means loss of registration. Insurance The organisers bear no responsibility for untoward events in connection with, before, during and after the course. Participants are strongly advised to take out their own personal and travel insurance coverage. Important deadlines 06/08/2007: replacement deadline 03/09/2007: registration deadline G
  8. 8. REGISTRATION FORM 1ST GLOBAL INSIGHT CONFERENCE ON LEUKAEMIA, 10-11 SEPTEMBER 2007, Mumbai, India Please fill in this form in BLOCK CAPITALS and send to Chatrina Melcher - European School of Oncology - Bellinzona Office IOSI Ospedale Reg. Bellinzona e Valli - CH-6500 Bellinzona - Switzerland Tel: +41 91 811 8050 - Fax: +41 91 811 8051 - Email: eso2@esoncology.org ONLINE REGISTRATION AVAILABLE AT www.cancerworld.org/eso PARTICIPANT'S DETAILS Surname Name Institute Department City, Country Personal Address Job Address Street Zip Code City Country Tel Fax Mobile (with international prefix) Email Fiscal Code (only for Italian residents) Profession Specialization Main field REGISTRATION FEE RESIDENT IN INDIA OR SURROUNDING COUNTRIES € 35 INTERNATIONAL PARTICIPANT € 270 INTERNATIONAL PARTICIPANT, CLUB ESO MEMBER € 216 Payment must accompany the registration form and be processed by 03/09/2007. The registration fee covers admission to the course, a copy of the programme, coffee and lunch throughout the course as indicated in the programme. PAYMENT DETAILS: CREDIT CARD: Visa/Mastercard American Express Card No / / / Expiry date / Card holder’s name in CAPITAL LETTERS Card holder’s signature CHEQUE payable to the European School of Oncology (enclose cheque) BANK TRANSFER with no cost to the beneficiary addressed to: European School of Oncology Bank: Banca Popolare di Milano, Agenzia 24 - Milan, Italy Account holder: European School of Oncology Number: No. 16333 IBAN: IT96G0558401624 0000000 16333 - BIC BPMIITM1024 Reference: "Leukaemia" + your name Please enclose a copy of the bank transfer to your registration form I authorize the European School of Oncology to use my personal data according to what is specified in Article 13 DLGS 196, Available at www.cancerworld.org or on request at fax number +39 02 8546 4545. Signature Date

×